

The logo for RUUA Bioscience, featuring the letters 'RUUA' in a stylized, white, outlined font. The 'R' and 'A' have a unique, angular design. The background is a dark green with lighter green, swirling, organic patterns.

BIOSCIENCE

Hui a Tau

Annual Shareholders Meeting

4th November 2024

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading distributor of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.

How to participate in virtual/hybrid meetings (Q&A)


Shareholder and proxyholder Q&A participation

Written questions

Questions may be submitted ahead of the meeting. If you have a question to submit during the live meeting, please select the Q&A tab on the right half of your screen at any time. Type your question into the field and press submit. Your question will be immediately submitted.

Help

The Q&A tab can also be used for immediate help. If you need assistance, please submit your query in the same manner as typing a question and a Computershare representative will respond to you directly.




How to participate in virtual/hybrid meetings (Voting)

Shareholder and proxyholder voting

Once the voting has been opened, the resolutions and voting options will allow voting.

To vote, simply click on the Vote tab, and select your voting direction from the options shown on the screen. You can vote for all resolutions at once or by each resolution.

Your vote has been cast when the tick appears. To change your vote, select 'Change Your Vote'.



Board of Directors Te Poari Ringatohu



Anna Stove

Chair

A 25+ years track record leading transformational change within the pharmaceutical sector, having held senior executive roles in NZ, Asia Pacific and Europe.



Panapa Ehau

Executive Director,
Co-Founder

Co-founder of a number of social enterprises. Holds governance roles across numerous for-profit and charitable organisations.



Teresa Ciprian

Non-Executive Director

Global expertise in innovation, commercialisation, marketing and business development in the primary sector.



Tony Barclay

Non-Executive Director

Over 30 years' experience in business, with 22 years of healthcare expertise. Holds Directorships in private MedTech companies.



Kale Panoho

Board Observer

An entrepreneur at heart having started multiple successful technology businesses out of the US and NZ.

Agenda

Raranggi take

1. Company overview and Chair's address
2. Chief Executive Officer's presentation
3. Annual results presentation
4. Shareholder questions
5. Ordinary resolutions
 - a) Auditor's remuneration
 - b) Issue of New Ordinary Shares
6. General business



Company overview and Chair's address

Te tirohanga whanui o te
kamupene me te korero a
te Heamana

Rua's unique growth strategy

Te rautaki whakatupu ahurea o Rua

- Capital-light approach
- R&D and genetic discovery in Ruatorea
- Outsource cultivation and manufacturing
- Establishing distribution channels in export markets



IRUA

Unique genetics selected at Ruatorea

Partner with best in class for low cost, scalable delivery.

We work with cultivation and manufacturing companies closer to our key markets. This allows Rua to grow our revenues in a capital-light manner.

IRUA

Germany | Australia | UK
Aotearoa New Zealand | Poland
| Czechia

Achievements at a glance

Mawhiti mai ki nga whakatutukitanga



Established short-term revenue pipelines to fill with unique legacy genetics.



Extended the distribution contract with Nimbus Health in Germany for an additional three years and to include many other European countries.



Achieved first revenues in Australia, and developed solid sales and distribution channels for a comprehensive product range.



Signed a distribution agreement with Target Healthcare in the United Kingdom.



Received approval from Ministry of Health NZ for two new products for the New Zealand market.



Secured agreements to undertake cultivation trials in Portugal, to supply the European market.



Signed an offtake agreement with a New Zealand cultivator to export Rua's legacy genetics to Australia.

Subsequent activity



In July 2024, Rua launched new dried flower products for the German and New Zealand markets.



Rua requires additional capital to fund growth opportunities

Rua is seeking to raise ~NZ\$3,1m of new equity

- Working capital funding for growth
- The cash raised, both from the facility sale and capital raise, is intended (if fully subscribed) to fund the business to a self-sustaining position.

Chief Executive Officer's presentation

Te whakatakotoranga o te
Kaiwhakahaere Matua



IRUA

FY24: An overview Tirohanga whanui

- Established sales footprint in Australian market
- Established supply lines into four key markets



IRUA

Unique genetics selected at Ruatorea.

Partner with best in class for low cost, scalable delivery.

We work with cultivation and manufacturing companies closer to our key markets. This allows RUA to grow our revenues in a capital-light manner.

IRUA

Germany | Australia Aotearoa
New Zealand | UK | Poland |
Czechia

Global progress







Kokiri ki te ao

United Kingdom

Germany

Czechia

Poland

	Aotearoa New Zealand	Two new products approved.
	Australia	First sales in FY24, established new distribution channels.
	United Kingdom	Signed distribution agreement with Target Healthcare.
	Germany	Extended contract with Nimbus Health and established supply.
	Poland	Five-year supply agreement with Motagon.
	Czechia	Five-year supply agreement with Motagon.

Australia

Aotearoa
New Zealand



Germany

- Largest and most developed medicinal cannabis market in Europe, if not the world.
- Changes in regulations in April 2024 saw considerable growth in the market.
- Extended agreement with Nimbus Healthcare for an additional three year term.
- July 24 we launched a new dried flower product which is driving an increase in sales.



Australia

- One of the larger medicinal cannabis markets in the world at approx. \$450m.
- In August 2023 we took delivery of our first product and made it available for sale.
- We employed our first Australian based employee, John Sanders as the Chief of Sales and Marketing to drive sales and reinforce relationships.
- Expanded the portfolio during the year to include new product formats and legacy genetic from Aotearoa.



United Kingdom

- Signed distribution agreement with Target Healthcare
- Have subsequently established a supply pipeline meeting the necessary regulatory requirements.
- Products expected in the market in November 24



Aotearoa New Zealand

- We received approval for two dried flower products from the Ministry of Health
- First sales in July 24.
- New product expected in November 24
- Two further product applications have been initiated.

Impact Programme

Nga hotaka whakaawe

Compassionate Access Programme

- In FY24 we expanded the programme through the support of our supply network and partners to 52 patients per month.



Impact Programme

Nga hotaka whakaawe

Scholarship Programme

Focusing on inspiring the next generation of scientists and entrepreneurs.

- 12 scholarships awarded
- 2 Industry trips to Auckland and Wellington
- 1 Internship
- 3 Kura visits to Mangaoporo



Rua's FY24 GHG report


Te ripoata GHG o Rua mo FY24

- Scope 1 and 2 emissions reduced by 20%
- Scope 3 emissions a challenge

Total GHG emissions tCO₂-e



Total GHG emissions by scope tCO₂-e



GHG emissions by source (%) FY24

- 55% Purchased Goods and Services
- 24% Business Travel
- 9% Fleet Fuels - Diesel
- 7% Electricity
- 5% Other

Our plans for FY25

Te mahere o Rua FY25

Revenue from customers

\$3–5 mill

New products

Legacy genetics to Germany and Australia

Two new products in New Zealand and Germany

New markets

United Kingdom

IRUA

BDO

FY24 financial
commentary

Nga korero mo nga putea



Financial commentary
Profit & loss
Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2024.

Rua establishes in all markets

Revenue from customers

\$86k

Total revenue and other income

\$322k

Loss before tax

-\$13.7m

Financial commentary

Balance sheet

Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2023.

Rua requires further capital

Cash and investments

\$0.90m

Total assets

\$7.74m

Total liabilities

\$0.97m

Net assets

\$6.77m

Financial commentary

Cashflow

Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2024.

Investing in the future

Net cash outflow from operating activities

\$3.74m

Net cash inflow from investing activities

\$2.21m

Net cash outflow from financing activities


\$95k

Financial commentary

Operational expenditure

Nga korero mo nga putea

Rolling 12month average monthly expenditure
(\$000)



Financial commentary

Sales Revenue

Nga korero mo nga putea

Quarterly sales revenue, all markets
(\$000)



An aerial photograph of a coastline. The top half shows the ocean with white-capped waves breaking onto a sandy beach. The bottom half shows a rocky coastline with dark, jagged rocks meeting the water. The overall color palette is dominated by blues, greens, and browns.

Shareholder questions

Nga patai a nga kaipupuri hea



Ordinary resolutions

Whakataunga noa

RUA

Resolution One

That the Board be authorised to fix the auditor's remuneration.



RUA

Resolution Two

That the Board are authorised to issue New Shares

- Up to 37,311,522 shares
- At a price of not less than 3c per share
- At any time during the next 12 months



General business

Nga take hakirikiri

The image features a logo for 'RUUA BIOSCIENCE' centered on a background of dark green, wavy, organic patterns. The word 'RUUA' is written in a large, white, stylized, sans-serif font with a double-line effect. Below it, the word 'BIOSCIENCE' is written in a smaller, white, all-caps, sans-serif font.

RUUA

BIOSCIENCE